Navigation Links
The Launch of Five Immunomodulatory Therapies for Relapsing Forms of Multiple Sclerosis Will Contribute to 4 Percent Annual Growth of the Total Market from 2013 to 2023
Date:8/7/2014

BURLINGTON, Mass., Aug. 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, coupled with the expected U.S. approval of Genzyme/Sanofi/Bayer HealthCare's Lemtrada, will help drive total sales across the multiple sclerosis (MS) market in the United States, France, Germany, Italy, Spain, United Kingdom and Japan to over $20 billion in 2023, reflecting 4 percent annual growth from 2013. Of note, future generics and projected biosimilar competition will cause major-market sales to contract in the latter part of our study period from a 2018 peak of over $22 billion.

Other key findings from the Pharmacor report entitled Multiple Sclerosis:

  • U.S. market dominance of Tecfidera: With greater cross-trial efficacy on relapses than injectable agents, few serious safety risks or monitoring requirements and acceptable tolerability, Tecfidera has experienced robust uptake in the United States. The drug is forecast to become the U.S. market leader by 2015, supported by gradually declining reliance on the platform injectable therapies.
  • Success for follow-on injectables: Despite physicians' and patients' enthusiasm for oral disease-modifying therapies, injectable products remain important current treatment options and comprise a meaningful element of the MS pipeline. We forecast that both Plegridy and Teva's Copaxone 40 mg three-times weekly, two follow-on products offering improved dosing characteristics over time-tested clinical mainstays, will help sustain these companies' respective franchises and earn blockbuster sales during the forecast period.
  • Ocrelizumab's clinical and commercial promise: Interviewed experts express positive opinions about ocrelizumab's potential for strong efficacy in MS as well as its relatively favorable delivery profile. Interviewed thought leaders are quick to note that the drug's safety must be established in ongoing Phase III studies, but they are cautiously optimistic that ocrelizumab may become a preferred agent in later-line MS treatment.

Comments from Decision Resources Group Analyst John Crowley, Ph.D.:

  • "Continued clinical success with anti-inflammatory compounds accentuates the unmet need for bona fide neuroprotective or regenerative therapies for MS. Such an agent could be initiated early in the disease process and/or in combination with immunological agents to benefit the entire spectrum of MS patients. Development in this arena is active—notably with Biogen Idec's Phase II candidate BIIB-033—but advancement overall is constrained by the difficulty of identifying valid drug targets and the optimal design for clinical trials."
  • "Interviewed experts routinely note the pressing unmet need for effective therapies to treat progressive forms of MS. Although experts generally report low expectations for ongoing clinical trials assessing drugs like Tysabri, Gilenya and ocrelizumab, the commercial potential for a successful agent is sizable—we expect a drug's approval for secondary- or primary-progressive MS could result in sales exceeding $1 billion in that population alone."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Z Trim Launches Food-Grade Biofiber Gum
2. OSTAR Launches Its A Series Cloud Based Telehealth Vital Signs Patient Monitoring System
3. SOLS Systems Announces Nationwide Launch Of 3D Printed Orthotics
4. Janssen Launches Online Healthy Minds Video Series
5. AARC Launches Virtual Museum
6. InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada
7. Drew Crawford Announces Launch of PBM365 Media
8. CPhI South America 2014 Launches with Generics Showing Huge Growth
9. Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services
10. MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe
11. UBM Medica US Launches NeurologyTimes.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):